secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-08-11T20:03:25+00:00
Accession:  0001193125-26-344559
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene hosts Aug 11 virtual KOL event on NMIBC market research insights
-----------------------------------------------------------------------

- Virtual KOL event held August 11, 2026 to discuss emerging non-muscle invasive bladder cancer (NMIBC) market research.
- Presentation filed as Exhibit 99.1; company positioned as non-viral genetic medicine developer.
- No clinical data, financial results, or guidance disclosed in the filing; exhibit contains only title and disclaimers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/0001193125-26-344559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526344559/engn-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer